Description

Product Description

PNC-27 (CAS No. 1159861-00-3) is a chimeric therapeutic research peptide designed to model the tumor-suppressive functions of p53 while enhancing cell penetration and selectivity. It consists of a p53 peptide sequence fused to penetratin, a transduction domain known for facilitating intracellular delivery. This hybrid structure allows PNC-27 to mimic p53 tumor suppressor activity and directly induce cancer cell death.

Molecular Design and Origin

The peptide was engineered to bind HDM-2 (also known as MDM2), an oncogenic protein that normally degrades p53 and suppresses its activity. By mimicking p53’s binding interface, PNC-27 competitively associates with HDM-2, restoring tumor-suppressive signaling and destabilizing cancer cell survival pathways.

Unlike conventional small molecules, PNC-27 exhibits direct cytotoxicity through membrane pore formation. Upon binding HDM-2, it localizes to the cancer cell membrane, where it induces selective pore formation leading to osmotic imbalance, membrane rupture, and cell lysis. Notably, this activity shows selectivity for malignant cells, sparing normal tissues in multiple preclinical observations.

Research Relevance

• Cancer Biology: Provides a model system for studying tumor-suppressor pathways.

• Oncology Drug Discovery: Serves as a reference compound in peptide-based anticancer research.

• Leukemia Models: Particularly relevant in acute myeloid leukemia (AML) research, where HDM-2 overexpression is common.

• Membrane Biophysics: Allows researchers to study peptide-induced pore formation.

GMP-grade production ensures purity, consistency, and reproducibility, enabling preclinical investigations in both in vitro and in vivo models.

Disclaimer: For laboratory research use only. Not for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

PNC-27 represents a dual-function anticancer research peptide with unique molecular features:

Mechanism of Action

1. HDM-2 Binding

   • Mimics the p53 peptide structure to bind HDM-2.

   • Prevents HDM-2–mediated degradation of p53.

   • Restores tumor suppressor signaling.

2. Membrane Targeting

   • PNC-27 selectively associates with cancer cell membranes.

   • Incorporates into the lipid bilayer with high specificity.

3. Pore Formation and Cell Lysis

   • Induces pore formation across malignant cell membranes.

   • Causes osmotic imbalance, membrane rupture, and necrotic cell death.

   • Demonstrates selectivity: preferentially lyses malignant cells while sparing healthy cells.

Research Applications

• Oncology Research: Provides a model for selective peptide-based anticancer activity.

• Leukemia Studies: Evaluated for activity in acute myeloid leukemia cell lines and preclinical systems.

• Cancer Cell Biology: Investigating mechanisms of pore-forming peptides.

• Drug Resistance Studies: Exploring PNC-27 activity in multidrug-resistant cancer cells.

• Translational Research: Potential insights into next-generation peptide therapeutics.

  

Side Effects (For Reference in Research Models)

In preclinical and in vitro research contexts, PNC-27 has shown:

• Cancer Cell Selectivity: Strong lytic activity against malignant cells; negligible toxicity in normal cells at equivalent doses.

• Membrane Sensitivity: Lysis depends on cell membrane composition and HDM-2 localization.

• Dose-Dependent Cytotoxicity: Higher concentrations accelerate lytic kinetics.

• Off-Target Risks: At supra-physiological doses, limited effects on normal cell membranes may occur.

• Stability Considerations: Freeze-thaw cycles or prolonged exposure to aqueous solutions may reduce activity.

• Experimental Variability: Activity levels differ among cancer cell types, requiring optimization in study design.

 These data are derived from laboratory models only and do not imply clinical safety or efficacy.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• PNC-27

• PNC-27 CAS 1159861-00-3

• p53 penetratin chimeric peptide

• HDM-2 binding peptide

• Anticancer research peptide

• Cancer cell lysis peptide

• Acute myeloid leukemia research compound

• GMP-grade PNC-27 supplier

• Peptide pore-forming agent

• Laboratory-only oncology peptide